key: cord-0949862-llm01dz4
authors: Chapman, Mackenzie E.; Daczkowski, Courtney M.; Ghosh, Arun K.; Mesecar, Andrew D.
title: Catalytic function and substrate specificity of alpha and beta coronavirus papain-like proteases: targeting human NL63, SARS-CoV and SARS-CoV-2 (Covid-19) with designed inhibitors
date: 2022-02-11
journal: Biophysical Journal
DOI: 10.1016/j.bpj.2021.11.1792
sha: b049a3a494133deed28acb86d87dfa43fe9b8e84
doc_id: 949862
cord_uid: llm01dz4

nan

Development of a cytochrome P450 CYP3A7 quantitative structureinhibitory relationship (QSIR) model to assess drug safety in neonates Hannah M. Work, Sylvie E. Kandel, Jed N. Lampe. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA. Cytochrome P450s (CYPs) are a superfamily of human enzymes predominantly involved in the metabolism of drugs, xenobiotics, and many endogenous substrates. Assessing the inhibitory effect investigational new drugs exert on CYPs is essential because inhibition may lead to toxicity due to drug accumulation and/or adverse drug-drug interactions. Inhibition is initially predicted using adult-relevant in silico models (e.g., QSAR/QSIR, 3D pharmacophores, etc.). These models are based upon data obtained from previous in vitro high-throughput screening results. Currently, no in silico model exists for CYP3A7, the predominant hepatic CYP enzyme expressed in neonates and developing infants. To help identify the risk new drugs pose to this fragile patient population prior to administration, a reliable model most be developed that can predict CYP3A7 inhibition. Using the recently published CYP3A7 crystal structure, an FDA-approved drug library was screened in silico using SchrodingerÒ Glide in order to determine the binding and inhibitory capacities these drugs may have on CYP3A7. The positive hits were further analyzed to determine their half-maximal inhibitory concentration (IC 50 ) using a neonate-relevant high-throughput screening assay previously developed by our lab. The resulting IC 50 values along with physical characteristics of the inhibitors were inputted into the SchrodingerÒ Phase QSAR Software to develop our model, and common features between inhibitors of CYP3A7 were identified. These findings provide insight on what physical characteristics should be avoided when developing drugs specific for this fragile patient population.

Applying molecular dynamics to elucidate binding interactions for developing opioid overdose therapeutics Emily N. Robinson. Biochemistry and Biophysics, University of Rochester, Rochester, NY, USA. Opioid overdose kills 128 people every day in the United States. While there are treatments for opioid overdose, there are currently no therapeutic tools to prevent it. Moreover, these treatments are limited to emergency scenarios, most notably due to induction of withdrawal and loss of analgesia. Fatal opioid overdoses are primarily attributed to opioid-induced respiratory depression (OIRD). As part of an ongoing collaboration, a class of cysteine esters have been identified that reverse OIRD without blocking the analgesic effects of the opioid or inducing withdrawal. The current hypothesis is that these esters function by binding b-arresting, a protein that signals downstream of the opioid receptors. The primary goal of my proposed work is to characterize this binding interaction to (i) rationalize the trends currently observed in the preliminary data and (ii) suggest new compounds with superior performance. Specifically, I will apply molecular dynamics simulation techniques to elucidate the molecular interactions of these cysteine esters. The results of these simulations will aid in advancing the current understand-ing of their function in stopping the OIRD response. Using these techniques, I have identified preliminary binding sites of these cysteine esters to the inactive structures of b-arrestin 1 and b-arrestin 2. Going forward, I will use alchemical free energy calculations to determine the affinity of the candidate binding sites; the results will be tested experimentally by collaborators using surface plasmon resonance and hydrogen-deuterium mass spectroscopy.

Biophysical analyses of the HRSV NS2 protein: insights about its interaction with flavonol morin by spectroscopy technique Isabella O. de Lourenço 1,2 , J essica M. de Sá 1,2 , Artemiza S. Miranda 2 , Icaro P. Caruso 2,3 , Marcelo A. Fossey 1,2 , Fátima P. de Souza 1,2 . 1 Physics, Universidade Estadual Paulista (UNESP), São Jos e do Rio Preto, Brazil, 2 Multiuser Center for Biomolecular Innovation, UNESP, São Jos e do Rio Preto, Brazil, 3 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. The human respiratory syncytial virus is the main cause agent of several respiratory diseases, such as pneumonia and bronchiolitis. The hRSV NS2 protein may act by inhibiting or neutralizing different stages of the interferon pathway, suppressing the ability of the cell to establish an antiviral state. This protein, containing 15 kDa, has no homology with other proteins, and its structure was recently resolved. Thus, the investigation for promising ligands that could interact with the NS2 protein and block its action is a way to search for potential antivirals. The aims of this study were expressed, purified, characterized the NS2 protein and the interaction between NS2 with the flavonol morin. The protein was expressed in BL21(DE3) and it was purified by affinity and molecular size exclusion chromatography. The estimative of secondary structural percentage was determined by circular dichroism (CD) at 25 C, and the investigation of the NS2/morin interaction was performed using fluorescence spectroscopy by titrating at three different temperatures. The CD results have shown a percentage composition of secondary structure of 15% of a-helix, 35% of b-strand, 23% of turns, and 27% of random coil. The fluorescence results showed an increase in Stern Volmer constant (K SV ) with increment of temperature, indicating that the quenching process occurs due to a collision mechanism, and the interaction presents a binding constant (k b ) on order of 10 4 M À1 with stoichiometry binding of 1:1. From the outcomes observed herein, the NS2/morin interaction was considered moderate, suggesting that the flavonoid morin might be a potential inhibitor of NS2 function, disturbing its interaction with other partner macromolecules. Acknowledgments: FAPESP, FINEP, and CNPq. There is currently an urgent need to develop new and effective anticoronavirus therapeutics. Coronaviruses encode two essential proteases, the papain-like protease (PLpro) and the 3C-like protease. PLpros are cysteine proteases that are involved in polyprotein processing of three nonstructural proteins encoded in the virus, and also are involved in evading the innate immune response by having deubiquitinating and deISGylating activity. In our study, the catalytic function and substrate specificity of multiple PLpros from both Alphaand Beta-CoVs. The X-ray structure of NL63 PLP2 was determined to 2.1 Å and is the first X-ray structure of a human Alpha-CoV. A preliminary X-ray structure of the Bulgarian Bat CoV PLpro, a potential zoonotic CoV for SARS and SARS-CoV-2, has also been determined to 3.4 Å . We probed the active sites of these PLpros using a series of small-molecule inhibitors we designed. This series of inhibitors have shown low micromolar IC 50 s against SARS-CoV and SARS-CoV-2 PLpros and some begin to show inhibition of NL63 PLP2. As more structural information (i.e. inhibitor-bound and substrate-bound structures) becomes available for PLpro, we now have insights into optimizing various inhibitors using structure-based drug design as well as starting to develop a broadspectrum papain-like protease inhibitor. COVID-19, caused by the SARS-CoV-2 virus, continues to cause widespread disruption to all aspects of society. The SARS-CoV-2 virion is studded by trimeric spike proteins that play the predominant role in initiating viral invasion by binding to human angiotensin-converting enzyme 2 (hACE2). However, contact between SARS-CoV-2 and hACE2 is merely half of the invasion story, ignoring the complexity of other necessary infection cofactors on the mammalian cell surface. All cell surfaces are surrounded by a glycocalyx composed of various glycoconjugates, including glycoproteins, glycosphingolipids, and proteoglycans. Many pathogens exploit these glycoconjugates as attachment factors and receptors for infection, including influenza, herpes simplex, human immunodeficiency virus, and coronaviruses (SARS-CoV and MERS). Heparan sulfate is a long, negatively charged, linear polysaccharide and a component of particular interest in the glycocalyx. Esko and coworkers have shown that spike protein binds to cell surface HS and hACE2 in a cooperative manner, and furthermore that heparan sulfate is required for host-cell invasion by SARS-CoV-2. Using extensive ensemble-based docking simulations to incorporate protein and glycan motions, we elucidated important clues regarding how heparan sulfate and other glycocalyx components bind the spike glycoprotein during the SARS-CoV-2 host-cell invasion. We identified 7 novel heparan sulfate-spike binding sites and validated 7 literature-proposed binding sites. Through use of a ''binding site importance score,'' we posited which sites are most likely to be required for anchoring to cellular heparan sulfate for ultimate initiation of cell invasion. Because we incorporated both protein and glycan flexibility in our analysis, we were able to elucidate two key mechanistic hypotheses: (1) GAGs are likely to bind in multiple compensatory modes to accommodate changes in spike conformation, and (2) the spike's glycans compete with GAGs for certain binding sites on the spike's surface yet stabilize other GAG-spike interactions.

Dimethyl sulfoxide (DMSO) affects activity of SARS-CoV-2 main protease Marquise G. Crosby 1 , Gemma R. Takahashi 1 , Rachel W. Martin 2 , Elizabeth Diessner 2 , Brenna Norton-Baker 3 , Carter T. Butts 3 . 1 Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA, 2 Department of Chemistry, University of California Irvine, Irvine, CA, USA, 3 University of California Irvine, Irvine, CA, USA. The SARS-CoV-2 main protease (re) is necessary for viral replication and is therefore the subject of intense inhibitor development efforts. We find that this enzyme is active at very high concentrations of dimethyl sulfoxide (DMSO), a common co-solvent for inhibitor candidates. The enzyme has enhanced activity with increasing DMSO, reaching a maximum at 33%. The impact of this additive has a profound effect on activity assays: in water/DMSO solutions, modest inhibitors appear to be inactive, while poor inhibitors appear to act as agonists. Molecular dynamics simulations suggest DMSO does not binding to a specific site, but rather changes the conformation of the enzyme, particularly near the active site and at the C-terminus. However, experiments indicate that it remains in the dimer form rather than dissociating even at concentrations where it is inactive.

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, continues to cause widespread devastation to the global community. The SARS-CoV-2 virion is studded by $30 trimeric spike proteins, which themselves play the predominant role in initiating viral invasion by binding to human angiotensin-converting enzyme 2 (hACE2). However, this simple model of spike and hACE2 binding is merely half of the story. All cell surfaces are surrounded by a dense sugary matrix, called the glycocalyx, which is composed of various types of glycoconjugates, including N-linked and O-linked glycoproteins, glycosphingolipids, and proteoglycans. Many pathogens exploit these glycoconjugates as attachment factors and receptors for infection, including, but not limited to, coronaviruses. Heparan sulfate (HS) -a long, negatively charged, linear polysaccharide -is a vital proteoglycan in glycocalyx that is known to play a co-factorial role for many viruses. In our current work, via extensive ensemble-based docking simulations to incorporate protein and glycan motions, we have elucidated important clues as to how heparan sulfate and other glycocalyx components bind the spike glycoprotein during the SARS-CoV-2 host-cell invasion. We identified 7 novel heparan sulfate-spike binding sites and validated 7 literature proposed binding sites. Additionally, through use of a ''binding site importance score,'' we have posited which sites are most likely to be required for anchoring to cellular heparan sulfate for ultimate initiation of cell invasion. Finally, since we incorporated both protein and glycan flexibility in our analysis, we were able to elucidate two key mechanistic hypotheses: (1) GAGs are likely to bind in multiple compensatory modes to accommodate changes in spike conformation, and (2) the spike's glycans compete with GAGs for certain binding sites on the spike's surface yet stabilize other GAG-spike interactions. 933-Pos Developing inhibitors of the SARS-CoV-2 main protease Christian Seitz 1 , Vedran Markota 1

SARS-CoV-2 is the causative virus of the global pandemic disease COVID-19, causing a significant public health burden. With the continued spread of SARS-CoV-2 comes an urgent need for drugs to treat those infected. The main protease (M pro , also known as 3CL) of SARS-CoV-2 is a validated drug target. We created a pipeline to computationally screen molecules on a variety of M pro pockets and pocket sizes, identified with enhanced sampling molecular dynamics simulations before carrying the putative hits forward to in vitro and in vivo assays for hit validation and optimization